Clinical Trial to Evaluate the Tolerance of TQB2210 Injection

Clinical trial NCT06929195 · COMPLETED

Trial details

NCT number: NCT06929195
Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Advanced Malignant Tumours

Start date: 2025-05-16
Primary completion: 2026-04-10
Enrollment: 16

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.